Ineresting story in yesterday's NEW YORK TIMES (p. A6). Bristol-Myers is to allow the newest and most powerful AIDS drug (atanazavir - a second line treatment for those who have developed resistance to their first anti-viral cocktails) to be licensed to generic drug makers in India and South Africa without charge. The generic companies will set the pricing for the drug in Africa and India. The drug was introduced only last year in many 'wealthy countries'. One problem seems to be the need for a heat-stable version of ritonavir, the booster drug with which this new drug is administered. This booster drug is manufactured by Abbott Laboratories.